Heart Damage After COVID-19 Recovery
The world faces new repercussions of COVID-19 as we continue to navigate this pandemic. In the following, article from Cardiovascular Business, patients and healthcare providers are presented with a summary of a German study. This study investigated the cardiovascular ramifications that result from COVID-19 infection. According to the study, 78 out of 100 patients studied showed signs of heart damage after recovery from COVID-19.
As a result, it is essential that healthcare providers can accurately and efficiently acquire imaging data in order to better direct patient care. The Freeland Systems Team knows this and provides excellent cloud-based PACS that provides anytime, anywhere access to patient images and reports. Our PACS, “cPAC,” provides more efficient and powerful tools for better patient care. Reach out to our team today for more information.
Below you can read the Cardiovascular Business article by Michael Walter that summarizes the study.
Cardiac involvement and myocardial inflammation are common in recovered COVID-19 patients, according to a new study published in JAMA Cardiology.
The authors studied cardiac imaging results of 100 adult patients included in the University Hospital Frankfurt COVID-19 Registry. All patients had confirmed cases of COVID-19 but passed a swab test after at least two weeks in isolation. They were recruited for this analysis between April to June 2020.
The team tracked patients who had experienced a wide variety of outcomes after their diagnosis. Just two of the 100 patients had to undergo mechanical ventilation, for example, and oxygen supplementation was required in 28 patients.
All participants underwent cardiac MR imaging using “standardized and unified” protocols on 3T MRI scanners. The cohort was compared with 50 healthy control patients and 57 risk factor-matched patients.
Overall, the team found that 78 patients had abnormal imaging findings. Findings included raised myocardial native T1 (73 patients), raised myocardial native T2 (60 patients), myocardial late gadolinium enhancement (32 patients) and pericardial enhancement (22 patients). Three patients underwent a biopsy after severe abnormalities were detected; “active lymphocytic inflammation” was present in these patients, but “no evidence of any viral genome.”
“The results of our study provide important insights into the prevalence of cardiovascular involvement in the early convalescent stage,” wrote lead author Valentina O. Puntmann, MD, PhD, University Hospital Frankfurt in Germany, and colleagues. “Our findings demonstrate that participants with a relative paucity of preexisting cardiovascular condition and with mostly home-based recovery had frequent cardiac inflammatory involvement, which was similar to the hospitalized subgroup with regards to severity and extent. Our observations are concordant with early case reports in hospitalized patients showing a frequent presence of late gadolinium enhancement, diffuse inflammatory involvement, and significant rise of troponin T levels.”
In addition, the team wrote, cardiac involvement appears to occur independent of the severity of the original COVID-19 infection. Additional research with a larger cohort is necessary, they added.
The full study from JAMA Cardiology is available here.